ClinicalTrials.gg
CompletedNCT05768360Updated Jul 13, 2023

A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects

A Phase 1 interventional study of Savolitinib and Digoxin in Healthy Male Subjects, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will assess the effects of savolitinib on the pharmacokinetics (PK) of substrates of human transporters digoxin (P-gp), rosuvastatin (OATP1B1/3), metformin (OCT2, MATE1/2K), and furosemide (OAT1/3) in healthy male subjects, performed at a single clinical unit.

Read the detailed description

This study will be performed at a single clinical unit.

Subjects will be admitted to the clinical unit on Day -1 of Period 1 and Period 2. Subjects will have a washout period of 14 days between Period 1 and Period 2.

Period 1: Subjects will recieve a single dose of a drug cocktail of 4 medications (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E).

Period 2: Participants will receive savolitinib (Dose A) in combination with the drug cocktail of 4 medications as received in Period 1.

The study will consist of 4 visits:

Visit 1 (Enrollment): Following full written informed consent, subjects will be screened for eligibility.

Visit 2 (Period 1: Treatment and Sample Collection Period): Each subject will be admitted to the clinical unit on Day -1 of Period 1, single dose of drug cocktail is administered on Day 1, and remain in clinical unit until Day 5 assessments. A washout period of 14 days is followed.

Visit 3 (Period 2: Treatment and Sample Collection Period): Each subject will be admitted to the clinical unit on Day -1 of Period 2, single dose of savolitinib and drug cocktail is administered, and remain in clinical unit until Day 5 assessments.

Visit 4 (Follow-up): Subjects will attend the clinical unit for a final Follow-up Visit 5 to 7 days post Day 5 in Period 2.

Each subject will be involved in the study for 9 weeks including screening to final follow up.

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • Drug-Drug Interaction
  • Substrate of human drug transporters
  • Fixed-sequence
  • Drug cocktail
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects must use barrier (condoms) during sexual intercourse with a female partner of during the study and for 6 months after the last dose of the IMPs medical products (IMPs).
  2. Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  3. Regular bowel movements (ie, on average production of at least 1 stool per day).

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder
  2. History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.
  4. Any clinically significant abnormalities on 12-lead (ECG) at screening and/or first admission to the clinical unit, as judged by the investigator.
  5. >450 ms or QT ≥500 ms or other ECG abnormality making interpretation more difficult, as judged by the investigator, or a history of additional risk factors for Torsades de Points (eg heart failure, hypokalemia, family history of long QT syndrome), which in the opinion of the investigator may put the subject at risk.
  6. Any positive result on screening for serum surface antigen OR anti-HBc antibody, indicative of active hepatitis B (ie, subjects with positive anti-HBc antibody result are acceptable if anti HBc IgM antibodies are negative), antibody, and antibody.
  7. History of latent or chronic infections (eg, tuberculosis, recurrent sinusitis, genital herpes, urinary tract infections) or at risk of infection.
  8. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months (12 weeks) or within 5 half-lives of the drug, whichever is longer, of Visit 2 (Day -1 of Period 1) in this study or participation in a method development study (no drug) 1 month prior to Visit 2. The period of exclusion ends 3 months after the final dose or after 5 elimination half-lives of the drug or 1 month after the last visit, whichever is the longer.
  9. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to savolitinib, or drug cocktail medications or their .
  10. Subject has clinical signs and symptoms consistent with Coronavirus disease (COVID-19), eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission unless confirmed by a negative severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test (SARS-CoV-2 PCR test).
  11. Vulnerable subjects, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  12. Positive screen for drugs of abuse or cotinine at screening or on each admission to the clinical unit or positive screen for alcohol on each admission to the clinical unit.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Drug cocktail/Savolitinib + Drug cocktail

    Subjects will receive two different interventions in two periods (Periods 1 and 2). In Period 1, the subjects will receive a single-dose of Drug cocktail components (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E). During Period 2, the subjects will receive savolitinib dose A in combination with the Drug cocktail components.

    Drug: Savolitinib · Drug: Digoxin · Drug: Metformin Hydrochloride · Drug: Rosuvastatin · Drug: Furosemide

Interventions

  • The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

  • The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

  • The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

  • The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

  • The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

06

What researchers measure

Primary outcomes

  1. Plasma Area Under Concentration-time Curve from zero to infinity (AUCinf) of the drug cocktail components

    To evaluate AUCinf of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2)

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  2. Plasma Area under the concentration-curve from zero to the last quantifiable concentration (AUClast) of the drug cocktail components

    To evaluate AUClast of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2)

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  3. Plasma partial area under the concentration-time curve from time 0 to time t post-dose (AUC(0-t)) of the drug cocktail components

    To evaluate (AUC(0-t)) of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  4. Maximum observed plasma drug concentration (Cmax) of drug cocktail components

    To evaluate Cmax of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  5. The ratio of plasma AUCinf (R AUCinf) of the drug cocktail components in the presence and absence of savolitinib

    To evaluate AUCinf ratio of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  6. The ratio of plasma AUC(0-t) (R AUC(0-t)) of the drug cocktail components in the presence and absence of savolitinib

    To evaluate AUC(0-t) ratio of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  7. The ratio of plasma Cmax (R Cmax) of drug cocktail components in the presence and absence of savolitinib

    To evaluate Cmax ratio of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

Secondary outcomes

  1. Number of participants with adverse events

    To assess safety and tolerability of savolitinib following oral dosing.

    Time frame: Day 1 in Periods 1 (Week 1) and 2 (Week 4) to Day 7 (follow-up after last Pharmacokinetic (PK) sample)

  2. Area under plasma concentration-time curve from zero to infinity (AUCinf) of savolitinib and its metabolites (M2 and M3)

    To assess AUCinf of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  3. Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUCinflast) of savolitinib and its metabolites (M2 and M3)

    To assess AUClast of savolitinib and its metabolites (M2 and M3)

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  4. Partial area under the concentration-time curve from time 0 to time t post-dose (AUC(0-t)) of savolitinib and its metabolites (M2 and M3)

    To assess AUC(0-t) of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  5. Maximum observed plasma (peak) drug concentration (Cmax) of savolitinib and its metabolites (M2 and M3) of savolitinib and its metabolites (M2 and M3)

    To assess Cmax of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  6. Observed lowest concentration before the next dose is administered (Ctrough) of savolitinib and its metabolites (M2 and M3)

    To assess Ctrough of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  7. Terminal elimination half-life (t½λz) of savolitinib and its metabolites (M2 and M3)

    To assess t½λz of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  8. Time to reach maximum observed concentration (tmax) of savolitinib and its metabolites (M2 and M3)

    To assess tmax of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  9. Apparent volume of distribution based on the terminal phase (Vz/F) of savolitinib and its metabolites (M2 and M3)

    To assess Vz/F of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  10. Apparent total body clearance (CL/F) of savolitinib and its metabolites (M2 and M3)

    To assess CL/F of savolitinib and its metabolites (M2 and M3).

    Time frame: Day 1 and Day 2 in Period 2 (Week 4)

  11. Maximum observed plasma (peak) drug concentration (Cmax) of cocktail parent components

    To assess the Cmax of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  12. Time to reach maximum observed plasma concentration (Tmax) of the cocktail parent components

    To assess the PK parameter tmax of the drug cocktail parent components

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  13. Plasma terminal elimination half-life (t½λz) of cocktail parent components

    To assess the PK parameter t½λz of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  14. Plasma terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz) of cocktail parent components

    To assess the PK parameter λz of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  15. Plasma Apparent total body clearance (CL/F) of cocktail parent components

    To assess the PK parameter CL/F of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  16. Plasma Apparent volume of distribution based on the terminal phase (Vz/F) of cocktail parent components

    To assess the PK parameter Vz/F of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  17. Renal clearance (CLR) of cocktail parent components

    To assess the urine PK parameter CLR of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  18. Cumulative amount of unchanged drug excreted into urine (Ae) of cocktail parent components

    To assess the urine PK parameter Ae of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  19. Cumulative amount of unchanged drug excreted into the urine from time 0 to time t (Ae(0-t)) of cocktail parent components

    To assess Ae(0-t) of the drug cocktail parent components

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  20. Percentage of dose excreted unchanged in urine from time 0 to t (fe(0-t)) of cocktail parent components

    To assess fe(0-t) of the drug cocktail parent components.

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

  21. Cumulative amount of unchanged drug excreted into urine (CumAe) of the cocktail parent components

    To assess CumAe of the drug cocktail parent components

    Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)

07

Study locations

1 site
  • Research Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jun 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Mar 14, 2023
StartActual
Apr 25, 2023
Primary completionActual
Jun 24, 2023
CompletionActual
Jun 24, 2023
Last update
Jul 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05768360
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Apr 25, 2023
Primary completion
Jun 24, 2023
Completion
Jun 24, 2023
Last update
Jul 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Savolitinib · Digoxin · Metformin · Rosuvastatin · Furosemide

Start the discussion